Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
Sponsor: Shandong Suncadia Medicine Co., Ltd.
Summary
The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of HRS-1301 in Participants With Dyslipidemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
189
Start Date
2025-11-25
Completion Date
2026-08
Last Updated
2025-12-12
Healthy Volunteers
No
Conditions
Interventions
HRS-1301
HRS-1301 Dose 1,oral
HRS-1301
HRS-1301 Dose 2,oral
HRS-1301
HRS-1301 Dose 3,oral
HRS-1301
HRS-1301 Dose 4,oral
Placebo
Placebo,oral
Locations (1)
The 2nd Affiliated Hospital of Harbin
Harbin, Heilongjiang, China